Article

Target Trial Emulation to Assess the Efficacy of the MVA-BN Vaccine as a Pre-Exposure Strategy in Individuals with Risk Factors for Mpox

2025-04-24

Abstract excerpt

<h4>Background: </h4> The MVA-BN vaccine is considered effective for preventing mpox in key populations, based on observational studies, though its effectiveness remains unconfirmed by randomized trials. Observational studies published to date rely on retrospective analyses of routine data, often missing information on relevant risk factors for mpox. <h4>Methods:</h4> Multi-country target trial emulation study wit...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 337d3f24-6b34-56a8-80e7-26842520ea41
DOI: 10.20944/preprints202504.2096.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Target Trial Emulation to Assess the Efficacy of the MVA-BN Vaccine as a Pre-Exposure Strategy in Individuals with Risk Factors for MpoxDOI 10.20944/preprints202504.2096.v1Read

Effect of JYNNEOS vaccination on mpox clinical progression among cisgender male cases with confirmed infectionSemantic proximity Read

Real-world effectiveness of mpox (monkeypox) vaccines: a systematic reviewSemantic proximity Read

Factors that influenced the course of the mpox outbreak in the Netherlands, 2022-2023Semantic proximity Read

Prevalence and risk factors of adverse effects after the first COVID-19 booster dose: evidence from GreeceSemantic proximity Read

Mpox clinical and epidemiological patterns in the Central African Republic: a systematic review and meta-analysisSemantic proximity Read

Mpox vaccine and infection-driven human immune signaturesSemantic proximity Read

Clinical and epidemiological characteristics among probable and confirmed patients with mpox in Sierra Leone reported from January to May 2025Semantic proximity Read

Immunological analysis of LC16m8 vaccine: preclinical and early clinical insights into mpoxSemantic proximity Read

Continued circulation of mpox: an epidemiological and phylogenetic assessment, European Region, 2023 to 2024Semantic proximity Read

Cost-Effectiveness of Vaccination Strategies to Control Future Mpox Outbreaks in EnglandSemantic proximity Read

Early underdetected dissemination across countries followed by extensive local transmission propelled the 2022 mpox epidemicSemantic proximity Read

Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From the CANOPY Clinical TrialSemantic proximity Read